129 related articles for article (PubMed ID: 34874277)
1. Reduced MHC class II expression in medullary thyroid cancer identifies patients with poor prognosis.
Ruan X; Yi J; Hu L; Zhi J; Zeng Y; Hou X; Huang J; Gu P; Hao W; Gao M; Pan Y; Wei S; Zheng X
Endocr Relat Cancer; 2022 Jan; 29(2):87-98. PubMed ID: 34874277
[TBL] [Abstract][Full Text] [Related]
2. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
Bagheri-Yarmand R; Williams MD; Grubbs EG; Gagel RF
J Clin Endocrinol Metab; 2017 Mar; 102(3):933-941. PubMed ID: 27935748
[TBL] [Abstract][Full Text] [Related]
3. Cofilin is a mediator of RET-promoted medullary thyroid carcinoma cell migration, invasion and proliferation.
Giardino E; Catalano R; Barbieri AM; Treppiedi D; Mangili F; Spada A; Arosio M; Mantovani G; Peverelli E
Mol Cell Endocrinol; 2019 Sep; 495():110519. PubMed ID: 31352037
[TBL] [Abstract][Full Text] [Related]
4. Diversity of mutations in the RET proto-oncogene and its oncogenic mechanism in medullary thyroid cancer.
Hedayati M; Zarif Yeganeh M; Sheikholeslami S; Afsari F
Crit Rev Clin Lab Sci; 2016 Aug; 53(4):217-27. PubMed ID: 26678667
[TBL] [Abstract][Full Text] [Related]
5. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.
Grubbs EG; Williams MD; Scheet P; Vattathil S; Perrier ND; Lee JE; Gagel RF; Hai T; Feng L; Cabanillas ME; Cote GJ
Thyroid; 2016 Nov; 26(11):1553-1562. PubMed ID: 27610696
[TBL] [Abstract][Full Text] [Related]
6.
Qi XP; Jin BY; Li PF; Wang S; Zhao YH; Cao ZL; Yu XH; Cheng J; Fang XD; Zhao JQ
Thyroid; 2019 Oct; 29(10):1447-1456. PubMed ID: 31364476
[No Abstract] [Full Text] [Related]
7. Selective repression of RET proto-oncogene in medullary thyroid carcinoma by a natural alkaloid berberine.
Kumarasamy VM; Shin YJ; White J; Sun D
BMC Cancer; 2015 Aug; 15():599. PubMed ID: 26307103
[TBL] [Abstract][Full Text] [Related]
8. Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification.
Mian C; Pennelli G; Barollo S; Cavedon E; Nacamulli D; Vianello F; Negro I; Pozza G; Boschin IM; Pelizzo MR; Rugge M; Mantero F; Girelli ME; Opocher G
Eur J Endocrinol; 2011 Jun; 164(6):971-6. PubMed ID: 21422198
[TBL] [Abstract][Full Text] [Related]
9. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
[TBL] [Abstract][Full Text] [Related]
10. Salinomycin and its derivatives as potent RET transcriptional inhibitors for the treatment of medullary thyroid carcinoma.
Alqahtani T; Kumarasamy VM; Huczyński A; Sun D
Int J Oncol; 2020 Jan; 56(1):348-358. PubMed ID: 31746350
[TBL] [Abstract][Full Text] [Related]
11. MiR-182 promotes cancer invasion by linking RET oncogene activated NF-κB to loss of the HES1/Notch1 regulatory circuit.
Spitschak A; Meier C; Kowtharapu B; Engelmann D; Pützer BM
Mol Cancer; 2017 Jan; 16(1):24. PubMed ID: 28122586
[TBL] [Abstract][Full Text] [Related]
12. RET Regulates Human Medullary Thyroid Cancer Cell Proliferation through CDK5 and STAT3 Activation.
Yue CH; Oner M; Chiu CY; Chen MC; Teng CL; Wang HY; Hsieh JT; Lai CH; Lin H
Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34207842
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas.
Ramone T; Romei C; Ciampi R; Tacito A; Piaggi P; Torregrossa L; Ugolini C; Elisei R
Endocrine; 2019 Sep; 65(3):623-629. PubMed ID: 31278686
[TBL] [Abstract][Full Text] [Related]
14. Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer.
Lopergolo A; Perrone R; Tortoreto M; Doria F; Beretta GL; Zuco V; Freccero M; Borrello MG; Lanzi C; Richter SN; Zaffaroni N; Folini M
Oncotarget; 2016 Aug; 7(31):49649-49663. PubMed ID: 27351133
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma.
Frank-Raue K; Machens A; Leidig-Bruckner G; Rondot S; Haag C; Schulze E; Lorenz A; Kreissl MC; Dralle H; Raue F; Schmid KW
Thyroid; 2013 Mar; 23(3):294-300. PubMed ID: 22946486
[TBL] [Abstract][Full Text] [Related]
16. RET Kinase-Regulated MicroRNA-153-3p Improves Therapeutic Efficacy in Medullary Thyroid Carcinoma.
Joo LJS; Weiss J; Gill AJ; Clifton-Bligh R; Brahmbhatt H; MacDiarmid JA; Gild ML; Robinson BG; Zhao JT; Sidhu SB
Thyroid; 2019 Jun; 29(6):830-844. PubMed ID: 30929576
[No Abstract] [Full Text] [Related]
17. Targeting RET to induce medullary thyroid cancer cell apoptosis: an antagonistic interplay between PI3K/Akt and p38MAPK/caspase-8 pathways.
Mazumdar M; Adhikary A; Chakraborty S; Mukherjee S; Manna A; Saha S; Mohanty S; Dutta A; Bhattacharjee P; Ray P; Chattopadhyay S; Banerjee S; Chakraborty J; Ray AK; Sa G; Das T
Apoptosis; 2013 May; 18(5):589-604. PubMed ID: 23329180
[TBL] [Abstract][Full Text] [Related]
18. Novel withanolides target medullary thyroid cancer through inhibition of both RET phosphorylation and the mammalian target of rapamycin pathway.
Samadi AK; Bazzill J; Zhang X; Gallagher R; Zhang H; Gollapudi R; Kindscher K; Timmermann B; Cohen MS
Surgery; 2012 Dec; 152(6):1238-47. PubMed ID: 23158190
[TBL] [Abstract][Full Text] [Related]
19. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
Dabelić N; Jukić T; Fröbe A
Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
[TBL] [Abstract][Full Text] [Related]
20. Demonstration of a potent RET transcriptional inhibitor for the treatment of medullary thyroid carcinoma based on an ellipticine derivative.
Kumarasamy VM; Sun D
Int J Oncol; 2017 Jul; 51(1):145-157. PubMed ID: 28498409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
